アトピー性皮膚炎治療薬の東南アジア市場

調査会社GBI Research社が発行したリサーチレポート(データ管理コード:GBIHC485MR)
◆英語タイトル:Atopic Dermatitis Therapeutics in Southeast Asia Markets to 2024 - Growth Driven by Rising Awareness and Expected Launch of Novel Therapies
◆発行会社/調査会社:GBI Research
◆商品コード:GBIHC485MR
◆発行日:2018年11月
◆調査対象地域:アジア太平洋
◆産業分野:医療・製薬
◆ページ数:113
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール(受注後24時間以内)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD4,995 ⇒換算¥544,455見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD9,990 ⇒換算¥1,088,910見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD14,985 ⇒換算¥1,633,365見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
GBI Research社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[アトピー性皮膚炎治療薬の東南アジア市場]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

Atopic Dermatitis Therapeutics in Southeast Asia Markets to 2024 – Growth Driven by Rising Awareness and Expected Launch of Novel Therapies
Summary

Atopic dermatitis (AD), also called atopic eczema, is a chronic, pruritic, inflammatory skin disease arising from a complex interrelationship of environmental, immunologic, genetic, and pharmacologic factors, with a characteristic phenotype and typically distributed skin lesions.

It is one of the most common skin diseases, affecting approximately 20% of children and 1-3% of adults globally. AD is a genetically complex, familial transmitted disease with a strong maternal influence; a child possesses a two-fold risk of developing the disease if one of the parents is affected and a three-fold risk if both are affected. Many studies reported that increasing urbanization, westernization of lifestyle, obesity, lack of physical exercise, stress, food allergies, and pollution increase the risk of AD.

The current marketed drug landscape in AD includes topical agents (corticosteroids and calcineurin inhibitors), systemic therapies (such as corticosteroids, cyclosporine, azathioprine, methotrexate and mycophenolatemofetil) and a biologic therapy (Dupixent). Topical steroids have been the mainstay of treatment for AD in both children and adults for the past half century.

The evolution in the understanding of the pathogenesis of AD has led to the discovery and development of several promising treatment options for AD. Recently, two new therapies have been approved for AD, Eucrisa (crisaborole) and Dupixent (dupilumab). However, currently Sanofi/Regeneron’sDupixent is the only targeted therapy that is available in Southeast Asia AD market.

The late-stage AD pipeline contains promising therapies that have the potential to achieve approval and launch over the forecast period. These include LEO Pharma’stralokinumab, Eli Lilly’s baricitinib, Kangstem Biotech’s furestem-AD, Pfizer’s PF-04965842 and Amorepacific’s PAC-14028. These new drugs will expand the options available to treat AD patients and contribute to overall market growth by offering novel treatment mechanisms.

Scope

- The Southeast Asia AD market will be valued at $848.6m in 2024, growing from $423.2m in2017, at a compound annual growth rate of 10.5%.
- What are the key factors driving the Southeast Asia AD treatment market?
- What classes of drugs dominate the market?
- How will the market respond to recent approval?
- How will novel IL-4Ra inhibitor therapy Dupixent, which holds first-to-market advantage, contribute to growth?
- The AD pipeline contains a range of molecule types and molecular targets, including those that are well established in AD and novel target therapies.
- Which classes of novel drugs are most prominent in the pipeline?
- What are the common targets and mechanisms of action of pipeline therapies?
- Late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.
- How have the late-stage therapies performed in clinical trials?
- What are the commercial prospects for the most promising late-stage products?
- How will the approval of tralokinumab, furestem-AD, baricitinib, PAC-14028 and PF-04965842, affect the competitive landscape?
- Various drivers and barriers will influence the market over the forecast period.
- Which factors are most likely to drive the market in these countries?
- What licensing and co-development deals have occurred within this therapy area since 2007?

Reasons to buy

This report will enable you to:
- Understand the current clinical and commercial landscape of AD by considering epidemiology, symptoms, etiology and pathophysiology, diagnosis, prognosis and treatment guidelines and options.
- Visualize the composition of the AD market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
- Identify key pipeline trends in terms of molecule type, administration route, molecular target, and novelty.
- Consider market opportunities and potential risks by examining trends in AD clinical trial size, duration, and failure rate by stage of development, molecule type, and molecular target.
- Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
- Predict AD market growth in the eight assessed Southeast Asian markets, with epidemiological and annual cost of therapy forecasts across South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam, and Indonesia, as well as the individual contributions of promising late-stage molecules to market growth.
- Discover trends in licensing and co-development deals concerning AD products and identify the major strategic consolidations that have shaped the commercial landscape.

*** レポート目次(コンテンツ)***

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 11
2.1 Disease Introduction 11
2.2 Epidemiology 11
2.3 Symptoms 12
2.4 Etiology and Pathophysiology 13
2.4.1 Etiology 13
2.4.2 Pathophysiology 14
2.5 Diagnosis 15
2.5.1 Hanifin and Rajka Diagnostic Criteria 15
2.5.2 UK Working Party’s Diagnostic Criteria 16
2.5.3 Biomarkers 16
2.6 Classification and Disease Stages 16
2.7 Prognosis 17
2.8 Treatment Options and Guidelines 17
2.8.1 Emollients 17
2.8.2 Topical corticosteroids 17
2.8.3 Topical calcineurin inhibitors 17
2.8.4 Antimicrobials 18
2.8.5 Systemic immunosuppressive therapy 18
2.8.6 Biologics 18
2.8.7 Other treatments 18
2.8.8 Wet wrap therapy 18
2.9 Treatment guidelines 19
3 Marketed Products 21
3.1 Overview 21
3.1.1 Dupixent (dupilumab) – Regeneron and Sanofi 21
3.1.2 Protopic (tacrolimus) – Astellas 23
3.1.3 Elidel (Pimecrolimus) – Novartis 25
3.1.4 Cyclosporine 26
3.1.5 Xolair (omalizumab) – Novartis and Genentech (Off-Label Therapy) 27
3.1.6 Eucrisa (crisaborole) – Pfizer 28
3.1.7 Other Therapeutic Drug Classes Used in Atopic Dermatitis 29
3.2 Comparative Efficacy and Safety of Marketed Products 30
4 Pipeline Analysis 33
4.1 Overview 33
4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 34
4.3 Pipeline by Molecular Target 36
4.4 Promising Pipeline Candidates 38
4.4.1 Tralokinumab – LEO Pharma 38
4.4.2 Furestem-AD – Kang Stem Biotech 39
4.4.3 Baricitinib – Eli Lilly and Incyte Corporation 41
4.4.4 PAC-14028- Amorepacific 42
4.4.5 PF-04965842 – Pfizer 43
4.5 Comparative Efficacy and Safety of Pipeline Products 43
4.6 Product Competitiveness Framework 45
5 Clinical Trial Analysis 47
5.1 Failure Rate 47
5.1.1 Overall Failure Rate 47
5.1.2 Failure Rate by Phase and Molecule Type 48
5.1.3 Failure Rate by Phase and Molecule Target 49
5.2 Clinical Trial Size 50
5.2.1 Patient Enrollment per Trial by Molecule Type and Stage of Development 50
5.2.2 Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development 51
5.2.3 Patient Enrollment per Product by Molecule Type and Stage of Development 52
5.2.4 Patient Enrollment per Product by Molecular Target and Stage of Development 53
5.3 Clinical Trial Duration 54
5.3.1 Clinical Trial Duration by Molecule Type 54
5.3.2 Clinical Trial Duration by Molecular Target 55
5.4 Competitive Clinical Trials Metrics Analysis 56
6 Multi-scenario Forecast 58
6.1 Geographical Market 58
6.2 Southeast Asian Markets 58
6.3 South Korea 61
6.3.1 Treatment Usage Patterns 61
6.3.2 Annual Cost of Therapy 62
6.3.3 Market Size 63
6.4 Singapore 64
6.4.1 Treatment Usage Patterns 64
6.4.2 Annual Cost of Therapy 65
6.4.3 Market Size 66
6.5 Taiwan 67
6.5.1 Treatment Usage Patterns 67
6.5.2 Annual Cost of Therapy 68
6.5.3 Market Size 69
6.6 Malaysia 70
6.6.1 Treatment Usage Patterns 70
6.6.2 Annual Cost of Therapy 71
6.6.3 Market Size 72
6.7 Philippines 73
6.7.1 Treatment Usage Patterns 73
6.7.2 Annual Cost of Therapy 73
6.7.3 Market Size 74
6.8 Thailand 75
6.8.1 Treatment Usage Patterns 75
6.8.2 Annual Cost of Therapy 76
6.8.3 Market Size 77
6.9 Vietnam 78
6.9.1 Treatment Usage Patterns 78
6.9.2 Annual Cost of Therapy 79
6.9.3 Market Size 80
6.10 Indonesia 80
6.10.1 Treatment Usage Patterns 80
6.10.2 Annual Cost of Therapy 81
6.10.3 Market Size 82
7 Drivers and Barriers 84
7.1 Drivers 84
7.1.1 Increasing awareness and diversified healthcare reform to boost market growth 84
7.1.2 Promising pipeline products that target unmet needs for AD 84
7.1.3 Restoring skin barrier function remains a key goal of disease management, meaning a continued need for moisturizers and topical agents 84
7.2 Barriers 85
7.2.1 First to second line of therapy is dominated by cheap, genericized topical drugs which create significant obstacles for novel drugs hoping to penetrate the market 85
7.2.2 Pediatric sufferers are the largest patient group and pose a high bar in terms of safety for new products 85
7.2.3 The complexity of the multiple etiologies that lead to AD means that treatment outcomes with existing drugs are not universal across all patient groups 85
8 Deals and Strategic Consolidations 86
8.1 Licensing Deals 86
8.1.1 Deals by Region and Value 86
8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 87
8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 87
8.1.4 Key Licensing Deals 90
8.2 Co-development Deals 91
8.2.1 Deals by region, value, year, stage of development, molecule type and molecular target 91
8.2.2 Key Co-development Deals 92
9 Appendix 93
9.1 All Pipeline Drugs by Stage of Development 93
9.1.1 Discovery 93
9.1.2 Preclinical 94
9.1.3 Phase I 96
9.1.4 Phase II 97
9.1.5 Phase III 98
9.2 Summary of Multi-Scenario Market Forecasts to 2024 99
9.2.1 Southeast Asia 99
9.2.2 South Korea 99
9.2.3 Singapore 100
9.2.4 Taiwan 100
9.2.5 Malaysia 101
9.2.6 Philippines 101
9.2.7 Thailand 102
9.2.8 Vietnam 102
9.2.9 Indonesia 103
9.3 Bibliography 103
9.4 Abbreviations 108
9.5 Research Methodology 109
9.5.1 Secondary Research 110
9.5.2 Marketed Product Profiles 110
9.5.3 Late-Stage Pipeline Candidates 110
9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products 110
9.5.5 Product Competitiveness Framework 111
9.5.6 Pipeline Analysis 111
9.5.7 Forecasting Model 111
9.5.8 Deals Data Analysis 112
9.6 Contact Us 113
9.7 Disclaimer 113

1.1 List of Tables
Table 1: Hanifin and Rajka Diagnostic Criteria 15
Table 2: UK Working Party’s Diagnostic Criteria 16
Table 3: Classification of Atopic Dermatitis Based on Severity, Symptoms and Impact on Quality of Life 16
Table 4: Atopic Dermatitis Therapeutics, Southeast Asia, Summary of Other Therapeutic Classes for Atopic Dermatitis 30
Table 5: Atopic Dermatitis Therapeutics Market, Global, Licensing Deals with Disclosed Deal Value, 2007-2018 91
Table 6: Atopic Dermatitis Therapeutics Market, Global, All Pipeline Products, Discovery, 2018 93
Table 7: Atopic Dermatitis Therapeutics Market, Global, All Pipeline Products, Preclinical, 2018 94
Table 8: Atopic Dermatitis Therapeutics Market, Global, All Pipeline Products, Phase I, 2018 96
Table 9: Atopic Dermatitis Therapeutics Market, Global, All Pipeline Products, Phase II, 2018 97
Table 10: Atopic Dermatitis Therapeutics Market, Global, All Pipeline Products, Phase III, 2018 98
Table 11: Atopic Dermatitis Therapeutics Market, Southeast Asia, Market Forecast, 2017-2024 99
Table 12: Atopic Dermatitis Therapeutics Market, South Korea, Market Forecast, 2017-2024 99
Table 13: Atopic Dermatitis Therapeutics Market, Singapore, Market Forecast, 2017-2024 100
Table 14: Atopic Dermatitis Therapeutics Market, Taiwan, Market Forecast, 2017-2024 100
Table 15: Atopic Dermatitis Therapeutics Market, Malaysia, Market Forecast, 2017-2024 101
Table 16: Atopic Dermatitis Therapeutics Market, Philippines, Market Forecast, 2017-2024 101
Table 17: Atopic Dermatitis Therapeutics Market, Thailand, Market Forecast, 2017-2024 102
Table 18: Atopic Dermatitis Therapeutics Market, Vietnam, Market Forecast, 2017-2024 102
Table 19: Atopic Dermatitis Therapeutics Market, Indonesia, Market Forecast, 2017-2024 103

1.2 List of Figures
Figure 1: Atopic Dermatitis Therapeutics, South Korea, Age-Specific Prevalence (%), 2012 12
Figure 2: Prevalence of Atopic Dermatitis Associated Symptoms 13
Figure 3: Treatment Algorithm for Atopic Dermatitis Based on Severity 20
Figure 4: Atopic Dermatitis Therapeutics Market, Comparative Efficacy and Safety Heatmap for Marketed Products for the Treatment of Atopic Dermatitis 32
Figure 5: Atopic Dermatitis Therapeutics Market, Global, Overview of Pipeline Products, 2018 35
Figure 6: Atopic Dermatitis Therapeutics Market, Global, Pipeline by Molecular Target, 2018 37
Figure 7: Atopic Dermatitis Therapeutics Market, Southeast Asia, Tralokinumab, Market Forecast ($m), 2021-2024 39
Figure 8: Atopic Dermatitis Therapeutics Market, Southeast Asia, Furestem-AD, Market Forecast ($m), 2021-2024 40
Figure 9: Atopic Dermatitis Therapeutics Market, Southeast Asia, Baricitinib, Market Forecast ($m), 2020-2024 42
Figure 10: Atopic Dermatitis Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products 45
Figure 11: Atopic Dermatitis Therapeutics Market, Competitor Matrix for AD Marketed and Pipeline Products 46
Figure 12: Atopic Dermatitis Therapeutics Market, Global, Average Clinical Trial Failure Rate (%), 2007-2018 48
Figure 13: Atopic Dermatitis Therapeutics Market, Global, Clinical Trial Failure Rates by Molecule Type (%), 2007-2018 49
Figure 14: Atopic Dermatitis Therapeutics Market, Global, Clinical Trial Failure Rates by Molecular Target (%), 2007-2018 50
Figure 15: Atopic Dermatitis Therapeutics Market, Global, Clinical Trial Size per Trial by Molecule Type (participants), 2007-2018 51
Figure 16: Atopic Dermatitis Therapeutics Market, Global, Clinical Trial Size per Trial by Molecular Target (participants), 2007-2018 52
Figure 17: Atopic Dermatitis Therapeutics Market, Global, Clinical Trial Size per Product by Molecule Type (participants), 2007-2018 53
Figure 18: Atopic Dermatitis Therapeutics Market, Global, Clinical Trial Size per Product by Molecular Target (participants), 2007-2018 54
Figure 19: Atopic Dermatitis Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2007-2018 55
Figure 20: Atopic Dermatitis Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2007-2018 56
Figure 21: Atopic Dermatitis Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type 56
Figure 22: Atopic Dermatitis Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target 57
Figure 23: Atopic Dermatitis Therapeutics Market, Southeast Asia, Treatment Usage Pattern (million), 2017-2024 59
Figure 24: Atopic Dermatitis Therapeutics Market, Southeast Asia, Market Size ($m), 2017-2024 60
Figure 25: Atopic Dermatitis Therapeutics Market, South Korea, Treatment Usage Patterns (million), 2017-2024 62
Figure 26: Atopic Dermatitis Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2017-2024 63
Figure 27: Atopic Dermatitis Therapeutics Market, South Korea, Market Size ($m), 2017-2024 64
Figure 28: Atopic Dermatitis Therapeutics Market, Singapore, Treatment Usage Patterns (million), 2017-2024 65
Figure 29: Atopic Dermatitis Therapeutics Market, Singapore, Annual Cost of Therapy ($), 2017-2024 66
Figure 30: Atopic Dermatitis Therapeutics Market, Singapore, Market Size ($m), 2017-2024 67
Figure 31: Atopic Dermatitis Therapeutics Market, Taiwan, Treatment Usage Patterns (million), 2017-2024 68
Figure 32: Atopic Dermatitis Therapeutics Market, Taiwan, Annual Cost of Therapy ($), 2017-2024 69
Figure 33: Atopic Dermatitis Therapeutics Market, Taiwan, Market Size ($m), 2017-2024 70
Figure 34: Atopic Dermatitis Therapeutics Market, Malaysia, Treatment Usage Patterns (million), 2017-2024 71
Figure 35: Atopic Dermatitis Therapeutics Market, Malaysia, Annual Cost of Therapy ($), 2017-2024 72
Figure 36: Atopic Dermatitis Therapeutics Market, Malaysia, Market Size ($m), 2017-2024 72
Figure 37: Atopic Dermatitis Therapeutics Market, Philippines, Treatment Usage Patterns (million), 2017-2024 73
Figure 38: Atopic Dermatitis Therapeutics Market, Philippines, Annual Cost of Therapy ($), 2017-2024 74
Figure 39: Atopic Dermatitis Therapeutics Market, Philippines, Market Size ($m), 2017-2024 75
Figure 40: Atopic Dermatitis Therapeutics Market, Thailand, Treatment Usage Patterns (million), 2017-2024 76
Figure 41: Atopic Dermatitis Therapeutics Market, Thailand, Annual Cost of Therapy ($), 2017-2024 77
Figure 42: Atopic Dermatitis Therapeutics Market, Thailand, Market Size ($m), 2017-2024 78
Figure 43: Atopic Dermatitis Therapeutics Market, Vietnam, Treatment Usage Patterns (million), 2017-2024 79
Figure 44: Atopic Dermatitis Therapeutics Market, Vietnam, Annual Cost of Therapy ($), 2017-2024 79
Figure 45: Atopic Dermatitis Therapeutics Market, Vietnam, Market Size ($m), 2017-2024 80
Figure 46: Atopic Dermatitis Therapeutics Market, Indonesia, Treatment Usage Patterns (million), 2017-2024 81
Figure 47: Atopic Dermatitis Therapeutics Market, Indonesia, Annual Cost of Therapy ($), 2017-2024 82
Figure 48: Atopic Dermatitis Therapeutics Market, Indonesia, Market Size ($m), 2017-2024 83
Figure 49:Atopic Dermatitis Therapeutics Market, Global, Licensing Deals by Region and Value, 2007-2018 86
Figure 50: Atopic Dermatitis Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2007-2018 87
Figure 51: Atopic Dermatitis Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2007-2018 88
Figure 52: Atopic Dermatitis Therapeutics, Global, Licensing Deals by Molecule Type and Stage of Development, 2007-2018 89
Figure 53: Atopic Dermatitis Therapeutics, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2007-2018 90
Figure 54:Atopic Dermatitis Therapeutics Market, Global, Co-development Deals by Region, 2007-2018 92

*** 掲載企業 ***



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(GBIHC485MR )"アトピー性皮膚炎治療薬の東南アジア市場" (英文:Atopic Dermatitis Therapeutics in Southeast Asia Markets to 2024 - Growth Driven by Rising Awareness and Expected Launch of Novel Therapies)はGBI Research社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。